Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Luca Issi
RBC

Luca Issi

RBC Capital
Wall Street Analyst
★★★☆☆
#1209
on 13Foresight · ranked by our own returns
48%
Success Rate
+0.2%
Average Return
47 of 97 calls profitable · -185.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 48% of Luca Issi's ratings turned a profit when each position was held for 1 year — averaging +0.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

112 Buy 61 Hold 0 Sell
Luca's Stock Coverage 30 ratings · 2026-11-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BBIO
BridgeBio Pharma
 Oct 30, 2026 BUY Strong Buy
+26.0% avg upside
36 analysts
$100.00
33.43% Upside
 +4.5% ·
ALNY
Alnylam Pharma
 Oct 29, 2026 BUY Strong Buy
+76.3% avg upside
53 analysts
$280.00
69.63% Upside
 -5.1% ·
MRNA
Moderna
 Oct 27, 2026 HOLD Hold
-48.5% avg upside
38 analysts
$130.00
41.29% Downside
 +7.4% ·
WVE
Wave Life Sciences
 Oct 27, 2026 BUY Strong Buy
+443.6% avg upside
30 analysts
$15.00
317.77% Upside
 -9.3% ·
AMGN
Amgen
 Oct 27, 2026 BUY Buy
-29.9% avg upside
57 analysts
$430.00
7.72% Downside
 +4.3% ·
ARGX
Argenx Se
 Oct 20, 2026 BUY Strong Buy
-8.2% avg upside
48 analysts
$1025.00
14.73% Upside
 +10.4% ·
BMRN
BioMarin Pharmaceutical
 Oct 08, 2026 HOLD Strong Buy
+63.6% avg upside
52 analysts
$62.00
6.04% Upside
 +4.3% ·
ASND
Ascendis Pharma
 Oct 08, 2026 BUY Strong Buy
+12.2% avg upside
29 analysts
$290.00
15.41% Upside
 +23.7% ·
RARE
Ultragenyx Pharmaceutical
 Oct 08, 2026 HOLD Strong Buy
+193.8% avg upside
36 analysts
$19.00
17.94% Upside
 +5.2% ·
AGIO
Agios Pharma
 Oct 08, 2026 HOLD Strong Buy
+99.0% avg upside
30 analysts
$32.00
4.77% Upside
 +0.3% ·
IONS
Ionis Pharmaceuticals
 Oct 08, 2026 BUY Strong Buy
+74.1% avg upside
44 analysts
$85.00
95.30% Upside
 -28.4% ·
CRBU
Caribou Biosciences
 Oct 06, 2026 HOLD Buy
+1510.4% avg upside
13 analysts
$1.00
136.34% Upside
 -65.5% ·
QURE
uniQure
 Oct 02, 2026 BUY Strong Buy
+121.1% avg upside
30 analysts
$48.00
93.23% Upside
 +1.5% ·
SLDB
Solid Biosciences
 Sep 16, 2026 BUY Strong Buy
+176.4% avg upside
26 analysts
$18.00
190.35% Upside
 -21.6% ·
DYN
Dyne Therapeutics
 Sep 08, 2026 BUY Strong Buy
+116.3% avg upside
31 analysts
$30.00
79.71% Upside
 -15.5% ·
ARWR
Arrowhead Pharmaceuticals
 Aug 30, 2026 BUY Strong Buy
+26.6% avg upside
29 analysts
$100.00
66.94% Upside
 -40.1% ·
GB:0QW0
arGEN X
 Aug 18, 2026 BUY Strong Buy
-23.5% avg upside
25 analysts
 — · ·
LXEO
Lexeo Therapeutics, Inc.
 Aug 12, 2026 BUY Strong Buy
+528.2% avg upside
11 analysts
$20.00
536.94% Upside
 -41.1% ·
ALLO
Allogene Therapeutics
 Aug 12, 2026 BUY Strong Buy
+1186.8% avg upside
28 analysts
$9.00
662.80% Upside
 -59.4% ·
KRRO
Korro Bio
 Aug 07, 2026 HOLD Strong Buy
+90.0% avg upside
19 analysts
$10.00
30.13% Downside
 +2.6% ·
NTLA
Intellia Therapeutics
 Aug 06, 2026 HOLD Buy
+187.2% avg upside
39 analysts
$15.00
20.28% Upside
 -13.7% ·
RGNX
RegenXBio
 Aug 06, 2026 BUY Strong Buy
+389.7% avg upside
25 analysts
$19.00
163.82% Upside
 -32.3% ·
BEAM
Beam Therapeutics
 Aug 05, 2026 HOLD Strong Buy
+91.1% avg upside
25 analysts
$26.00
4.54% Downside
 -15.7% ·
EDIT
Editas Medicine
 Aug 05, 2026 HOLD Buy
+398.5% avg upside
33 analysts
$4.00
49.77% Upside
 -21.1% ·
CRSP
Crispr Therapeutics AG
 Aug 03, 2026 HOLD Buy
+45.6% avg upside
41 analysts
$50.00
2.81% Downside
 -14.8% ·
FULC
Fulcrum Therapeutics
 Jun 02, 2026 HOLD Hold
+169.6% avg upside
14 analysts
$4.00
7.86% Upside
 +20.1% ·
SGMOQ
Sangamo Therapeutics
 May 14, 2026 HOLD Buy
+9563.8% avg upside
16 analysts
$2.00
1624.17% Upside
 -21.4% ·
MGTX
Meiragtx Holdings
 Nov 13, 2024 BUY Strong Buy
+166.7% avg upside
14 analysts
$11.00
16.01% Upside
 +17.3% ·
QTTB
Q32 Bio
 May 11, 2023 HOLD Buy
+523.8% avg upside
28 analysts
$54.00
506.08% Upside
 +51.5% ·
LENZ
LENZ Therapeutics
 Mar 21, 2023 HOLD Buy
+470.0% avg upside
17 analysts
$3.00
1.71% Downside
 +93.9% ·
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Luca Issi — Frequently Asked Questions
How accurate are Luca Issi's stock ratings?
Based on the calls 13Foresight could measure, about 48% of Luca's ratings were profitable over a one-year hold, with an average return of +0.2% per rating, or -185.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Luca ranked on 13Foresight?
Luca Issi is currently ranked #1209 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Luca cover?
Luca most recently has ratings on BBIO, ALNY, MRNA, WVE, AMGN, ARGX, BMRN, ASND, RARE, AGIO, IONS, CRBU and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.